Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Emyria advances cannabinoid and MDMA-analogue development with $3 million cap raise

Emyria advances cannabinoid and MDMA-analogue development with $3 million cap raise

Emyria Ltd (ASX:EMD) managing director Michael Winlow joins Proactive to highlight the success of a recent $3 million capital raise, which the company intends to leverage for cannabinoid registration and MDMA-analogue development. Cornerstone investor Tattarang’s Tenmile Ventures – a biotech-centred fund – and lead manager Sixty-Two Capital both made large contributions to the raise.

ASX #ProactiveInvestors #Emyria #MDMA #Cannabinoids #Biotech

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK